Anti-S protein [P17]
Catalogue Number: AB03449-23.0-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Shipping Condition: | Blue Ice |
| Unit(s): | 200 ug |
| Host name: | Rabbit |
| Clone: | P17 |
| Isotype: | IgG |
| Immunogen: | The original antibody was generated in the screening studies by using recombinant RBD of SARS-CoV-2 as a target against a fully human naive antibody library. |
| Application: | ELISA, IF, NT, InVivoA, SPR |
Additional Text
Gene Name
S
Purification
Purified
Antibody Clonality
Recombinant Monoclonal
Gene ID
43740568
Uniprot ID
P0DTC2
Storage Note
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity
Spike glycoprotein; Receptor Binding Domain; SARS CoV 2 S glycoprotein; COVID-19 Spike protein; RBD; Receptor Binding Domain; S glycoprotein; SARS coronavirus 2 S protein; SARS coronavirus 2 Spike Protein; SARS CoV 2 Spike protein; SARS CoV 2; SARS-CoV-2 S protein; SARSCoV2; SARS-COV-2 S protein; SARS-COV-2 Spike glycoprotein; SARSCOV2 Spike protein; Severe acute respiratory syndrome 2 spike glycoprotein; Severe acute respiratory syndrome virus 2 spike glycoprotein; S glycoprotein; E2; Peplomer protein
Application Notes
The specificity of the antibody was confirmed by ELISA analysis (EC50 = 29 pM). Surface plasmon resonance (SPR) assays demonstrated that the antibody bound to SARS-CoV-2 RBD with a high affinity of 96 pM. Immunofluorescence staining showed that the antibody prevented SARS-CoV-2 infection in a dosedependent manner in Vero cells. Pseudovirus neutralization assay (PSV) in Huh7 cells and standard 50% plaque reduction neutralization tests (PRNT) in Vero cells, both showed that the antibody exhibited stronger neutralizing activity with IC50 and PRNT50 values of 165 and 195 pM, respectively. The antibody conferred effective protection in animal models. The structure of the Fab fragment and a prefusion stabilized SARSCoV-2 S ectodomain trimer was characterized using single-particle cryo-EM. The antibody was employed together with H014 to develop a therapeutic antibody cocktail against SARS-CoV-2 with neutralizing properties (Yao et al., 2021; PMID: 33262452).
Short Description
This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format for improved compatibility with existing reagents assays and techniques.
AB03449-23.0 Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations